Clinical Trial Update: A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating MK-6837 as a monotherapy and in combination therapy for advanced/metastatic solid tumors is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MK-6837

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasm Metastasis | Phase 1 | Status: ACTIVE_NOT_RECRUITING